


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently amended): A compound of formula



wherein

R₁ is (C₁₋₄)alkyl[[],];

R₂ is unsubstituted (C₁₋₄)alkyl or (C₁₋₄)alkyl substituted by unsubstituted or substituted

- (C₆₋₁₈)aryl or
- (C₆₋₁₈)aryl annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, and S[[],]; and

R₃ is (C₆₋₁₈)aryl one or morefold substituted by

- halogen,
- halo(C₁₋₆)alkyl,
- halo(C₁₋₆)alkoxy,
- cyano,
- phenyl, or
- heterocyclyl having 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, and S.

Claim 2. (Currently amended): A compound of claim 1 wherein

R₁ is methyl[[],];

R₂ is methyl or

methyl substituted by


- quinolinyl,
- benzo[1,3]dioxolyl,
- phenyl,
- phenyl one or morefold substituted by halogen, halo(C₁₋₄)alkyl, (C₁₋₄)alkoxy, cyano, amino, dimethylamino, carboxy(C₁₋₂)alkylcarbonylamino, amino(C₁₋₂)alkylcarbonylamino, (C₂

₄)alkylenecarbonylamino, or heterocyclylcarbonyl(C₁₋₂)alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, and O[.];

- R₃ is phenyl one or morefold, e.g. 1- to 3-fold, substituted by

- halogen,
- halo(C₁₋₂)alkyl,
- halo(C₁₋₂)alkoxy,
- cyano,
- phenyl, or
- heterocyclyl, including aromatic, having 6 ring members and 2 nitrogen heteroatoms.

Claim 3. (Currently amended): A compound of claim 1 ~~or~~ 2 of formula



Claim 4. (Currently amended): A compound of ~~any one of claims 1 to 3~~ in the form of a salt.

Claim 5. (Currently amended): A compound of formula I according to ~~any one of claim 1 to 4~~ for use as a pharmaceutical.

Claim 6. (Currently amended): The use of a compound of ~~any one of claims 1 to 4~~ for the manufacture of a medicament for the treatment of disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions.

Claim 7. (Currently amended): A pharmaceutical composition comprising a compound of formula I according to ~~any one of claim 1 to 4~~ in association with at least one pharmaceutical excipient.

Claim 8. (Original): A pharmaceutical composition according to claim 7, further comprising another pharmaceutically active agent.

Claim 9. (Currently amended): A method for treatment of disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I according to ~~any one of claims 1 to 4~~.

Claim 10. (Currently amended): A method ~~according to claim 9~~ for treatment of disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions in a subject in need of such treatment, wherein a compound of ~~any one of~~ claims 1 [[to 4]] is ~~administered~~ administered in combination with another pharmaceutically active agent, either ~~simultaneously~~ simultaneously or in sequence.